Turner Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Turner Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Turner syndrome, also referred to as congenital ovarian hypoplasia syndrome, is a chromosomal disorder that affects development in females. It results when a female’s cells have one normal X chromosome and the other sex chromosome is either missing or structurally altered. About half of the population with Turner syndrome have monosomy X (45,XO). The other 50% of the population has a mosaic chromosomal component (45,X with mosaicism). Turner syndrome is typically not inherited, but it can be inherited in rare cases. Some patients with Turner syndrome can have a Y chromosome mosaicism. Although not a cause of Turner syndrome, SHOX (short stature homeobox-containing gene on the X- chromosome) is associated with the short stature found in Turner syndrome.
The Turner Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Turner Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Turner Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Turner Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Turner Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Turner Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Turner Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Ascendis Pharma ASBraasch Biotech LLC
Cavalry Biosciences Inc
Changchun GeneScience Pharmaceutical Co Ltd
Dong-A Socio Holdings Co Ltd
Novo Nordisk AS
Polus Inc
Xiamen Amoytop Biotech Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Turner Syndrome reports